All In Biotech

Drug Trial Radar · NCT00376168

A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

A Phase III, Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

32

Actual

Start

Aug 2007

Primary completion

Sep 2009

Study completion Oct 2009

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 14, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system. This is the second trial to utilize a recombinant active form of lysosomal enzyme, glucocerebrosidase, (human prGCD) which is expressed and purified in a bioreactor system from transformed carrot plant root cell line.

Conditions

  • Gaucher Disease

Interventions

  • Plant cell expressed recombinant glucocerebrosidase (prGCD)Drug

    Intravenous infusion every two weeks for 9 months

  • Plant cell expressed recombinant glucocerebrosidase (prGCD)Drug

    Intravenous infusion every 2 weeks for 9 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Spleen Volume Measured by MRI.Time frame: Baseline and 9 months

Locations

11 sites in 8 countries. Site status is shown where the registry gives one.

  • University Research Foundation for Lysosomal Storage Diseases

    Coral Springs, Florida

  • Division of Medical Genetics, Emory University School of Medicine

    Decatur, Georgia

  • New York University Medical Center

    New York, New York

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Pontificia Universidad Catolica de Chile

    Santiago, Chile

  • Rambam Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Universita "La Sapienza"

    Rome, Italy

  • Morningside Medi-Clinic

    Morningside, South Africa

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.